

Immunogenicity analysis following human immunodeficiency virus recombinant DNA and recombinant vaccinia virus Tian Tan prime-boost immunization

LIU CunXia^{1,2†}, DU ShouWen^{1,2†}, LI Chang^{2*}, WANG YuHang², WANG MaoPeng^{1,2}, LI Yi², YIN RongLan³, LI Xiao², REN DaYong^{1,2}, QIN YanQing², REN JingQiang^{1,2} & JIN NingYi^{2*}

¹College of Animal Science and Veterinary Medicine, Jilin University, Changchun 130062, China;

²Key Laboratory of Jilin Province for Zoonosis Prevention and Control, Institute of Military Veterinary, AMMS, Changchun 130122, China;

³Academy of Animal Science and Veterinary Medicine in Jilin Province, Changchun 130062, China

Received March 12, 2013; accepted April 13, 2013; published online May 3, 2013

This study assessed and compared the immunogenicity of various immunization strategies in mice using combinations of recombinant DNA (pCCMp24) and recombinant attenuated vaccinia virus Tian Tan (rddVTT_{-CCMp24}). Intramuscular immunization was performed on days 0 (prime) and 21 (boost). The immunogenicity of the vaccine schedules was determined by measuring human immunodeficiency virus (HIV)-specific binding antibody levels and cytokine (interleukin-2 and interleukin-4) concentrations in peripheral blood, analyzing lymphocyte proliferation capacity against HIV epitopes and CD4⁺/CD8⁺ cell ratio, and monitoring interferon-gamma levels at different times post-immunization. The results showed that pCCMp24, rddVTT_{-CCMp24} and their prime-boost immunization induced humoral and cellular immune responses. The pCCMp24/rddVTT_{-CCMp24} immunization strategy increased CD8⁺ T cells and induced more IFN- γ -secreting cells compared with single-shot rDNA. The prime-boost immunization strategy also induced the generation of cellular immunological memory to HIV epitope peptides. These results demonstrated that prime-boost immunization with rDNA and rddVTT_{-CCMp24} had a tendency to induce greater cellular immune response than single-shot vaccinations, especially IFN- γ response, providing a basis for further studies.

vaccinia virus Tian Tan, human immunodeficiency virus, recombinant DNA, prime-boost, immunogenicity

Citation: Liu C X, Du S W, Li C, et al. Immunogenicity analysis following human immunodeficiency virus recombinant DNA and recombinant vaccinia virus Tian Tan prime-boost immunization. *Sci China Life Sci*, 2013, 56: 531–540, doi: 10.1007/s11427-013-4484-2

Acquired immunodeficiency syndrome (AIDS) is an epidemic disease that is difficult to both prevent and treat. Designing and developing of an effective preventive or therapeutic AIDS vaccine has been a great challenge to public health and scientific research. Recent studies in AIDS vaccine development have involved using (i) vaccine vectors, such as modified vaccinia Ankara (MVA) [1,2], New York

vaccinia (NYVAC) [3], fowlpox virus (FPV) [4,5], and Ad5 [6,7], (ii) various human immunodeficiency virus (HIV) immunogens, such as *gp120* [8], *env* [9], *tat* [10], HIV multiple epitopes [11–13], and multi-genes [14,15], or (iii) different immunization routes and strategies [16,17]. Since the first AIDS vaccine trial in 1987, more than 230 vaccine trials have been conducted [18]. Unfortunately, most of these vaccines failed to induce protection against HIV infection [19]. In a recent phase III clinical trial (RV144) in Thailand, using ALVAC-HIV (a recombinant canarypox

†Contributed equally to this work

*Corresponding author (email: ningyij@hotmail.com; lichang78@163.com)

vector that expresses *gag*, *pol*, and *env* as prime and AIDSVAX B/E (a recombinant gp120 protein) as boost has shown 31.2% protective efficacy against HIV. This study has provided the first proof-of-concept for a successful HIV vaccine [20].

Recent studies have focused on developing novel DNA-based AIDS vaccines. However, to date, these vaccines have failed to confer protective efficacy in non-human primates and phase I/II human trials. To improve the immunogenicity of DNA-based vaccines, many new delivery methods and immunization strategies are being tested, including electroporation [21], repetitive vaccine injections [22], co-expression of cytokines, such as interleukin-12 (IL-12) [23], 4-1BBL [24], or granulocyte-macrophage colony-stimulating factor (GM-CSF) [25] as molecular adjuvants, and prime-boost immunization strategies using heterologous vaccines which encode similar antigens [26]. CpG oligodeoxynucleotides (ODN) are powerful immunomodulatory agents capable of enhancing innate immune responses and when used as an adjuvant to improve adaptive immune responses against pathogens [27–29]. Cholera toxin (CT) has the ability to prime memory CD8 T cells, which control bacterial and viral challenges [30]. In this study, CpG ODN and CT subunit B (CTB) served as adjuvants for DNA and recombinant viral vaccines.

Vaccinia virus-based vaccines expressing HIV-associated immunogens can induce both humoral and cellular immune responses [31]. In a phase I clinical trial, the recombinant virus rMVA expressing HIV-1 virus-like particles elicited different patterns of T cell and antibody responses when used alone or in combination with DNA vaccine [17]. Several studies have also shown that immune responses can be generated *in vivo* in small animals or non-human primates after boost immunization with recombinant poxvirus following rDNA [26]. This prime-boost strategy using HIV rDNA for priming and recombinant vaccinia virus for boosting has been pursued by many researchers. Studies in non-human primate models using the SHIV or SIV DNA vaccine for priming and recombinant MVA for boosting have demonstrated that this regimen helped reduce viral loads *in vivo* and controlled disease progression [32–34]. In healthy adults, regimens using a multiclade, multigene HIV-1 DNA vaccine for priming and MVA for boosting were considered safe and induced broad and potent immune responses [35,36]. Recent research has shown that rDNA and rMVA vaccines encoding multiple cytotoxic and helper T-lymphocyte epitopes of HIV-1 were weakly immunogenic but safe in HIV-1-uninfected, vaccinia virus-naïve adults [37].

In the current study, rDNA and attenuated vaccinia virus Tian Tan (VTT) vector vaccines were constructed using the antigen MEGNp24 developed previously [5,12,38]. Two important molecular adjuvants, CpG oligodeoxynucleotides (ODN) and cholera toxin subunit B (CTB), were combined

with the vaccines to further enhance immunogenicity. Immunogenicity was evaluated *in vitro* and *in vivo* in cell models and in mice administered with individual vaccines or in combination using the prime-boost regimen. Antigen-specific humoral and cellular immune responses were analyzed for each vaccine regimen.

1 Materials and methods

1.1 rDNA and vaccinia virus vaccines

In the current study, rDNA pVL-CCMp24 (pCCMp24) and recombinant attenuated vaccinia virus Tian Tan (rddVTT_{-CCMp24}) were prepared as described previously (Du et al., data not shown). The vaccines expressed 29 HIV dominant epitopes (24 CTL or CD8 T-cell epitopes and five B-cell epitopes), HIV-1 p24 protein, CpG ODN (5'-AAAAACGTTGACGTTAACGTTGACGTT-3'), and CTB. A schematic of the pCCMp24 and rddVTT_{-CCMp24} constructs is shown in Figure 1A. The vaccines were diluted to the required concentrations in phosphate-buffered saline (PBS, pH 7.4).

1.2 Immunization of mice

Six-week-old female BALB/c mice were purchased from the Laboratory Animal Center, Academy of Military Medical Sciences (Beijing, China). All animal experimental protocols were approved by the Institutional Animal Care and Use Committee of the Chinese Academy of Military Medical Science (10ZDGG007). The mice were divided into four groups of eight for immunization. Group 1 was injected intramuscularly (i.m.) with 100 µg pCCMp24, group 2 was injected i.m. with 100 µL of 1×10^6 PFU mL⁻¹ rddVTT_{-CCMp24}, group 3 was primed i.m. with 100 µg pCCMp24 and boosted with 100 µL of 1×10^6 PFU mL⁻¹ rddVTT_{-CCMp24}, and group 4 was injected i.m. with 100 µL PBS. Mice from each group were boosted three weeks after the prime vaccination using the same inoculums as for priming unless stated otherwise. The immunization schemes are shown in Figure 1B.

1.3 Preparation of splenocytes

The splenocytes of immunized mice were isolated by centrifugation with Ficoll-Hypaque lymphocyte isolation solution (TBD Science, China) according to the manufacturer's instructions. In brief, at 10 d post-booster immunization, red blood cells were treated with lysis buffer and washed twice with complete medium, and the splenocytes were suspended in complete culture medium (89% RPMI 1640; HyClone, China), 10% fetal bovine serum (HyClone), and 1% penicillin-streptomycin (HyClone). The splenocytes were then used for T cell measurements.




Figure 1 Schematic of pCCMp24 and rddVTT-CCMp24 construction (A) and immunization (B) and HIV specific antibody detection by ELISA (C). A, The fusion gene CCMP24 containing CpG ODN, CTB, and the multi-epitope gene (MEG), the 29 epitopes and HIV-1 p24 were inserted into the eukaryotic expression vector pVAX1 and expressed under the control of the human cytomegalovirus (CMV) promoter. CCMP24 was also introduced into the TJ2R (expressing thymidine kinase)-site of the genome of TE3L-deleted vaccinia virus Tian Tan (VTT) and expressed under vaccinia virus promoter PE/L. B, Mice were divided into four groups and vaccinated twice by intramuscular injection. C, ELISA-binding HIV-specific antibody responses elicited with different vaccines and different strategies. The serum samples from each group were collected at 7, 14, 21, and 30 d after vaccination and pre-immunization to ascertain anti-HIV IgG by ELISA. The total anti-HIV serum IgG at different periods is illustrated above. All data represent the mean ($n=6$) \pm SD.

1.4 Collection of serum samples

Blood samples were collected at 7, 14, 21, and 30 d following the initial vaccination (prime) and stored at 4°C for 1 h. The blood samples were centrifuged at 1000 \times g for 10 min, the sera were recovered and stored at -70°C until required for further testing. Sera from pre-immune mice were separated and included as the negative control.

1.5 HIV-specific antibody enzyme-linked immunosorbent assay (ELISA)

The HIV antibody detection kit (Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., Beijing, China) was used to measure HIV-1-specific antibody titers. Briefly, 96-well ELISA plates were coated with highly purified recombinant HIV-1 antigens. One hundred microliter serum samples (test samples, as well as positive and negative control sera) were

added to the appropriate wells, and the plates incubated at 37°C for 1 h in a humid environment. The plates were washed five times with 1 \times washing buffer and 100 μ L HRP-conjugate reagent was added. Complex formation was permitted to proceed for 30 min at 37°C in a humid environment. The plates were washed five times, and 50 μ L chromogen solutions A and B added to each well. Color formation was performed for approximately 30 min in the absence of light. Stop solution (50 μ L/well) was added to each well to conclude the reaction. The absorbance values for each well were read at 450 nm using a microplate reader.

1.6 Interleukin-2 (IL-2) and interleukin-4 (IL-4) ELISA assay

The concentrations of IL-2 and IL-4 present in the peripheral blood of mice following booster immunization was measured using serum samples harvested at 10 d post-

booster immunization using mouse IL-2 and IL-4 ELISA kits (GBD, USA) according to the manufacturer's instructions.

1.7 Lymphocyte proliferative assay

To assess the proliferative response of T lymphocytes against HIV-specific peptides, splenocytes were seeded in 96-well tissue culture plate at a cell density of 2.5×10^5 cells/well and co-cultured with HIV-1 peptide pools (gp160, VTVYYGVPVWK; Pol, VTIKIGGQLK; Rt, ILKEPVHGV; IN, LLWKGEAV; Vpr, FPRPWLHSL; Tat, RKKRR-QRRS; Nef, FPVRPQVPL, at 10 mg L^{-1} per peptide) as a specific antigenic stimulator and mitogen ConA as a positive control, for 72 h at 37°C in the presence of 5% CO_2 . Splenocytes cultured with medium alone (no stimulation) served as a negative control. Twenty microliters of WST-1 solution (Beyotime Institute of Biotechnology, Haimen, China) was added to each well and incubated for 4 h, prior to agitation for 1 min. The absorbance values were measured at 450 nm using an ELISA microplate reader. The proliferation of splenocytes was represented by the stimulation index (SI): $SI = \text{mean absorbance value } A_{450} \text{ of stimulated cells} / \text{mean absorbance value } A_{450} \text{ of negative control}$.

1.8 CD4⁺ and CD8⁺ T-cell subtype assay

About 1.0×10^6 splenocytes sampled from mice at 10 d post-booster immunization were washed with FACS buffer and then stained with PerCP/Cy5.5-labeled anti-mouse CD3, fluorescein isothiocyanate-labeled anti-mouse CD4, and phycoerythrin-labeled anti-mouse CD8 (BioLegend, CA, USA) at 4°C in the dark for 30 min. The samples were washed twice, fixed in PBS containing 1% paraformaldehyde and analyzed by flow cytometry using Coulter Epics XL (Beckman Coulter, USA). Statistical analysis of the percentage of CD3⁺CD4⁺ and CD3⁺CD8⁺ T lymphocytes was performed.

1.9 Interferon-gamma (IFN- γ) enzyme-linked immunosorbent spot (ELISPOT) assay

Vaccine and HIV-specific cellular immune responses in mice were evaluated by ELISPOT assay measurements of splenocyte IFN- γ secretion following stimulation with heat-inactivated recombinant vaccinia virus or HIV CTL epitope peptides. Briefly, 1.0×10^5 splenocytes were plated in triplicate in 96-well polyvinylidene difluoride membrane plates coated with captured antibody using a mouse IFN- γ precoated ELISPOT kit according to the manufacturer's instructions (Dakewe Biotech, Shenzhen, China). The cells were stimulated with either 10 μL heat-inactivated rddVTT-CCMp24 (1.0×10^6 PFU mL^{-1}) or a pool of HIV epitope peptides (gp160, VTVYYGVPVWK; Pol, VTIKIGGQLK; Rt, ILKEPVHGV; IN, LLWKGEAV; Vpr, FPRPWLHSL;

Tat, RKKRRQRRS; Nef, FPVRPQVPL, at 10 mg L^{-1} per peptide). Phytohemagglutinin ($2.5 \mu\text{g mL}^{-1}$) was used as the positive control. RPMI 1640 was used as the negative control. After stimulation for 24 h, the cells were washed, IFN- γ secreting cells developed using biotinylated antibody and streptavidin-HRP, and the cells counted with a Biosys Bioreader.

1.10 Statistical analysis

Statistical analysis and comparisons between immunization groups was performed using Graphpad Prism software (San Diego, CA, USA). Data are presented as the mean \pm standard deviation (SD). The significance of differences was calculated using the One-way ANOVA (two tailed, confidence intervals 95%), as indicated by the *P*-value. Differences with a *P*-value < 0.05 were considered to be statistically significant.

2 Results

2.1 HIV-specific antibody response induced by different regimens

HIV-specific IgG present in the peripheral blood of mice immunized with the nominated vaccines and immunization strategies was measured at 7, 14, 21, and 30 d post-immunization by ELISA (Figure 1B). The results demonstrated consistent changes in IgG levels between the immunized groups and the PBS control group. As shown in Figure 1C, at 14 d post-immunization, the total antibody levels increased and then decreased. Following booster administration at 21 d, HIV-specific IgG levels again increased. At 7 d post-prime, the total antibody levels were higher for all vaccine groups analyzed when compared with the PBS control group ($P < 0.05$), and the antibody levels produced after immunization with rddVTT-CCMp24 (Group 2) were markedly higher than for pCCMp24 (Group 1) ($P < 0.05$; Figure 1C). For the rDNA/virus prime-boost immunization group (Group 3), at 10 d post-boost with rddVTT-CCMp24, the antibodies increased faster 1.2 fold than for pCCMp24-boost. The above results suggest that rddVTT-CCMp24 induced HIV-specific IgG responses, and it is obvious that the use of rddVTT-CCMp24 can enhance the immune response as a booster.

2.2 IL-2 and IL-4 secretion induced by different regimens

The concentration of cytokines IL-2 and IL-4 in the peripheral blood of mice was determined using a double antibody ELISA. As shown in Figure 2A and B, the concentrations of IL-2 and IL-4 were markedly higher for all immunization groups analyzed when compared with the PBS control




Figure 2 IL-2 and IL-4 levels in peripheral blood measured by ELISA. Three serum samples from each group were collected at 30 d after prime vaccination and used to determine IL-2 and IL-4 levels (pg mL^{-1}). The data represent the mean ($n=6$) \pm SD. Asterisks indicate statistically significant differences relative to the PBS control; ***, $P<0.001$.

group ($P<0.01$). The results indicated that pCCMp24, rddVTT-CCMp24 and their prime-boost regimen all induced the generation and secretion of IL-2 and IL-4.

2.3 Splenic T-lymphocyte proliferation stimulated by different regimens

The proliferation of splenic T-lymphocytes from immunized mice was determined by the WST-1 cell proliferation assay. Figure 3 shows the SI values determined for splenic T-lymphocytes stimulated by HIV epitope peptides (Figure 3A), or the positive control ConA (Figure 3B). As shown in Figure 3A, the stimulation of T-lymphocytes by HIV epitope peptides resulted in significant differences in SI values for splenocytes from the rddVTT-CCMp24-only vaccine group (Group 2) and the rDNA/virus prime-boost group (Group 3) when compared with the PBS control group ($P<0.01$). No significant difference in SI values was observed between the rDNA-rDNA group (Group 1) and the PBS control group. These results indicate that both rVV-rVV and rDNA-rVV could stimulate a T-lymphocyte specific proliferative response to HIV peptides.

2.4 Flow cytometric analysis of splenocytes

The proportion of CD4⁺ and CD8⁺ T cells measured for each experimental group are presented in Figure 4. The DNA/virus prime-boost group (Group 3) and the rddVTT-CCMp24-only vaccine group (Group 2) had higher proportions of CD3⁺CD4⁺ ($P<0.05$) and CD3⁺CD8⁺ ($P<0.01$) T cells/ 10^6 splenocytes than the corresponding PBS control group. No significant difference between Group 2 and Group 3 was observed. However, the percentage of CD8⁺ T cells for the DNA/virus prime-boost group (Group 3) was higher than for both the pCCMp24-only vaccine group (Group 1) ($P<0.01$). In addition, the percentage of CD8⁺ T

cells for the rddVTT-CCMp24-only vaccine group was higher than for the corresponding pCCMp24-only vaccine group ($P<0.05$).

2.5 Increased IFN- γ secretion following prime-boost immunization and immunologic memory

To further evaluate the pCCMp24 and rddVTT-CCMp24 prime-boost immunization strategy, splenocytes from mice immunized with pCCMp24- or rddVTT-CCMp24-only vaccine, pCCMp24-rddVTT-CCMp24 prime-boost, and PBS control were isolated and assessed. The T cell responses were measured 30 d after the first immunization (10 d post-boost immunization) and at 90 d post-priming, by IFN- γ capture ELISPOT assay against inactivated rddVTT-CCMp24 and HIV epitope peptides (Figures 5 and 6). At 30 d post-prime immunization, and following stimulation with inactivated rddVTT-CCMp24, the three immunization groups had on average greater numbers of IFN- γ -positive spots (SFC)/ 10^5 splenocytes than did the PBS control group ($P<0.01$). This indicated that the immune responses were significantly enhanced for all immunization groups when compared with the PBS control group (Figures 5A and 6). The rddVTT-CCMp24-only vaccine group and pCCMp24-rddVTT-CCMp24 prime-boost group had considerably greater numbers of IFN- γ -positive spots (SFC)/ 10^5 splenocytes than was observed for the pCCMp24-only vaccine group ($P<0.01$). No significant differences were detected between Group 2 and Group 3 (Figures 5A and 6). After stimulation with HIV epitope peptides, the rddVTT-CCMp24-only vaccine group and pCCMp24-rddVTT-CCMp24 prime-boost group had greater numbers of SFC/ 10^5 splenocytes than both the pCCMp24-only and PBS control group ($P<0.01$; Figures 5B and 6). The pCCMp24-rddVTT-CCMp24 prime-boost group had greater numbers of SFC/ 10^5 splenocytes than did the rddVTT-CCMp24-only vaccine group ($P<0.01$; Figures 5B and




Figure 3 Proliferative analysis of splenocyte from mice immunized with pCCMp24, rddVTT-CCMp24, VTT, or PBS at 10 d post-immunization. Approximately 2.5×10^5 splenocytes from each group were stimulated with HIV epitope peptides or the positive control ConA. The stimulation index indicates the proliferative capacity of splenocytes from each group when stimulated with different agents. The data represents the mean ($n=6$) \pm SD. Asterisks represent statistically significant differences; **, $P < 0.01$; ***, $P < 0.001$.




Figure 4 Phenotypic analysis of CD4⁺ and CD8⁺ T cells performed with flow cytometry. Splenocytes obtained at 10 d post-immunization from mice immunized with rddVTT-CCMp24 or VTT were used to analyze the percentages of CD3⁺CD4⁺ and CD3⁺CD8⁺ T cells using flow cytometry. A, Bar graph presenting the percentages of CD3⁺CD4⁺ and CD3⁺CD8⁺ T cells per 10^6 splenocytes (mean \pm SD). Asterisks represent significant differences; *, $P < 0.05$; **, $P < 0.01$. B, Representative scatterplots depicting cell surface antigen staining. The percentages of CD3⁺CD4⁺ and CD3⁺CD8⁺ T cells per 10^6 splenocytes are indicated in the upper right corner.




Figure 5 T cell IFN- γ secretion measured by ELISPOT. About 1×10^5 splenocytes from mice immunized with pCCMp24, rddVTT_{-CCMp24}, VTT, or PBS at 30 d (A and B) and 90 d (C and D) after prime immunization were stimulated with inactivated rddVTT_{-CCMp24} (A and C) and HIV CTL epitope peptides (B and D). In each panel, the data represent the mean ($n=6$) \pm SD. Asterisks represent statistically significant differences; **, $P<0.01$.

6). These results indicate that the prime-boost immunization strategy could induce greater specific cellular immune responses than single-shot vaccinations against HIV epitopes.

At 90 d post-prime immunization (60 d post boost immunization), IFN- γ -positive spots (SFC)/ 10^5 splenocytes were measured for evaluating cellular immunologic memory. The average number of IFN- γ -positive spots/ 10^5 splenocytes for all immunization groups was greater against inactivated rddVTT_{-CCMp24} than for the corresponding PBS control group ($P<0.01$; Figure 5C). The pCCMp24-rddVTT_{-CCMp24} prime-boost group had greater numbers of SFC/ 10^5 splenocytes than did the pCCMp24-only group ($P<0.05$), rddVTT_{-CCMp24}-only group (not significant), and PBS group ($P<0.01$) against HIV epitopes (Figures 5D and 6). Interestingly, the pCCMp24-only group had higher average numbers of SFC/ 10^5 splenocytes than the rddVTT_{-CCMp24}-only group against HIV epitopes ($P<0.01$; Figure 5D). These results indicate that rddVTT_{-CCMp24} boost immunization following pCCMp24 priming could induce HIV-specific cellular immune responses and immunologic memory.

3 Discussion

Vaccination has greatly impacted the health of human and animals in the past. To date, vaccination still plays a crucial role in preventing and controlling infectious diseases and cancers. With regard to the development of an effective AIDS vaccine, a myriad of problems and challenges have been encountered by researchers across a number studies. Such challenges include using appropriate animal models for vaccine evaluation, and effective immunogen design and immunization strategies [19,39,40]. VAX003 and VAX004 based on recombinant gp120 could not delay disease progression in phase III human clinical trials, and the antibodies were unable to neutralize most HIV-1 strains [8,41]. Considering the high genetic variability of HIV, it seems unlikely that a single antigen would prove efficacious in protecting against HIV infection and disease progression. Therefore, antigen multimers, multi-epitope, or a combination of various antigens could be used to address this issue and to elicit a strong immune response against HIV [13,15].




Figure 6 Representative IFN- γ spot forming cells under the stimulation of HIV epitope peptides and inactivated rddVTT_{CCMp24} are shown. The splenocytes were isolated from mice immunized with pCCMp24, rddVTT_{CCMp24}, VTT, or PBS at 30 and 90 d post-prime immunization. Each spot represents one T lymphocyte-secreting IFN- γ .

In previous study, 29 predominant epitopes of HIV including 23 epitopes of HIV-1, three epitopes of HIV-2, a Th cell universal epitope, a B cell universal epitope, and a tetanus toxin epitope were selected to synthesize and form a fusion gene MEGN. The p24 protein of HIV-1 was inserted into the multi-epitopes, of the aforementioned fusion gene, and named MEGNp24. To enhance the immunogenicity of the immunogen, a CpG ODN motif and CTB sequence were included upstream of MEGNp24, and the antigen designated CCMp24.

Recombinant DNA vaccines and live recombinant virus-based vaccines are the focus of many studies. Recent studies have documented the use of a number of different vaccines including viral vector vaccines or recombinant proteins as a boost following priming in an attempt to enhance the immune response induced by a single vaccine. DNA priming followed by MVA boosting, and vice versa, may provide better protection against malaria infection in mice compared with using the DNA or MVA vector alone [42]. In a previous study, different administration sequences with recombinant DNA and recombinant poxvirus were investigated in our laboratory. In the present study, virus vector booster immunization following priming with DNA was applied. Although researchers do not completely understand the principle behind the enhanced immune response for prime-boost strategies or the reason why priming with the recombinant DNA is followed by another modality such as viral vector vaccine or recombinant protein, a number of

studies have documented the use of DNA/live viral recombinant in immunization regimens [43]. Several studies in non-human primates have demonstrated a significant improvement in immunogenicity for a single DNA vaccine when a viral vector vaccine was administered as a boost following priming [26]. Such synergy between DNA and viral vector vaccines was observed in non-human primates when used for boosting with poxviruses such as vaccinia virus [9,33,34,44,45], Ad5 [46,47] or vesicular stomatitis virus [48].

Two attenuated vaccinia virus strains, MVA and NYVAC, have been used as vectors in vaccine research [3,49,50]. MVA-based therapeutic vaccines have been used in the treatment of some major chronic infections, including viral hepatitis, AIDS, and tuberculosis. Phase 1 and 2 clinical trials for MVA-based therapeutic vaccines have started to show significant results and promise for the effective treatment of chronic infectious diseases [51]. In rhesus macaques, DNA-MVA vaccine schedules expressing SIVmac-239 *gag*, *pr*, *rt*, and *env* genes, elicited high numbers of CD4⁺ and CD8⁺ T cells, and high titers and avidity for Env-specific IgG [16]. In a recent phase I clinical trial (RISVAC02), an MVA-based HIV vaccine expressing the *env*, *gag*, *pol*, and *nef* proteins of HIV-1 subtype B (MVA-B) was safe, well tolerated, and elicited strong and durable T-cell and antibody responses in 75% and 95% of volunteers [52]. The recombinant vaccinia virus vaccine rddVTT_{CCMp24} used in this study was constructed previously

and based on an attenuated vaccinia virus Tian Tan (deletion of *TE3L* and *TK* genes).

In the present study, the immunogenicity of various immunization strategies using pCCMp24 and rddVTT_{CCMp24} expressing CTB, HIV multi-epitopes, and p24 protein (CCMp24) was investigated in mice. Booster administration of the rddVTT_{CCMp24} vaccine following DNA priming generated strong humoral and T cell responses, particularly IFN- γ -mediated cellular immune responses against HIV peptides. The prime-boost immunization schedule can induced more CD8⁺ T cells than vaccination with DNA (pCCMp24) or virus (rddVTT_{CCMp24}) alone (Figure 4). In addition, rddVTT_{CCMp24} booster immunization was necessary following DNA priming to enhance IFN- γ -mediated cellular immune responses upon stimulation by HIV peptide pools compared with single-shot DNA/DNA or virus/virus (Figure 5B and D). There was no significant difference in the levels of cytokines (IL-2 and IL-4) in peripheral blood for the three different immunization schedules (Figure 2). With regard to HIV-specific antibody, rddVTT_{CCMp24} booster immunization following DNA priming induced antibody production more rapidly than for the DNA booster, and the antibody levels showed no significant difference compared with virus/virus immunization (Figure 1C). These data may serve as a basis for future pre-clinical studies of recombinant DNA/vaccinia virus immunization schedules.

We thank Liu YanYu and Li Ping for their technical support during the animal studies. This work was supported by the National Natural Science Foundation of China (81001342), the National Basic Research Program of China (2011CB512110), and the National Mega Project on Major Infectious Diseases Prevention (2012ZX10001005-006).

- 1 Garcia-Arriaza J, Najera J L, Gomez C E, et al. A candidate HIV/AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L enhances memory HIV-1-specific T-cell responses. *PLoS ONE*, 2011, 6: e24244
- 2 Gomez C E, Perdiguero B, Jimenez V, et al. Systems analysis of MVA-C induced immune response reveals its significance as a vaccine candidate against HIV/AIDS of clade C. *PLoS ONE*, 2012, 7: e35485
- 3 Kibler K V, Gomez C E, Perdiguero B, et al. Improved NYVAC-based vaccine vectors. *PLoS ONE*, 2011, 6: e25674
- 4 Hemachandra A, Puls R L, Sirivichayakul S, et al. An HIV-1 clade A/E DNA prime, recombinant fowlpox virus boost vaccine is safe, but non-immunogenic in a randomized phase I/IIa trial in Thai volunteers at low risk of HIV infection. *Hum Vaccin*, 2010, 6: 835-840
- 5 Song Y, Zhang L S, Wang H, et al. Immune responses of mice to prime-boost vaccination with the recombinant DNA and Fowlpox virus both expressing HIV-2 Gag-gp105. *Acta Virol*, 2010, 54: 293-296
- 6 Shiver J W, Fu T M, Chen L, et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. *Nature*, 2002, 415: 331-335
- 7 D'Souza M P, Frahm N. Adenovirus 5 serotype vector-specific immunity and HIV-1 infection: a tale of T cells and antibodies. *AIDS*, 2010, 24: 803-809
- 8 Pitisuttithum P, Gilbert P, Gurwith M, et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. *J Infect Dis*, 2006, 194: 1661-1671
- 9 Cox J H, Ferrari M G, Earl P, et al. Inclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine: Impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challenge. *Vaccine*, 2012, 30: 1830-1840
- 10 Ferrantelli F, Maggiorrella M T, Schiavoni I, et al. A combination HIV vaccine based on Tat and Env proteins was immunogenic and protected macaques from mucosal SHIV challenge in a pilot study. *Vaccine*, 2011, 29: 2918-2932
- 11 Sealy R, Slobod K S, Flynn P, et al. Preclinical and clinical development of a multi-envelope, DNA-virus-protein (D-V-P) HIV-1 vaccine. *Int Rev Immunol*, 2009, 28: 49-68
- 12 Li C, Shen Z, Li X, et al. Protection against SHIV-KB9 infection by combining rDNA and rFPV vaccines based on HIV multiepitope and p24 protein in Chinese rhesus macaques. *Clin Dev Immunol*, 2012, 2012: 958404
- 13 Sundaramurthi J C, Swaminathan S, Hanna L E. Resistance-associated epitopes of HIV-1C-highly probable candidates for a multi-epitope vaccine. *Immunogenetics*, 2012, 64: 767-772
- 14 Kovacs J M, Nkolola J P, Peng H, et al. HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120. *Proc Natl Acad Sci USA*, 2012, 109: 12111-12116
- 15 Stephenson K E, Sanmiguel A, Simmons N L, et al. Full-length HIV-1 immunogens induce greater magnitude and comparable breadth of T lymphocyte responses to conserved HIV-1 regions compared with conserved-region-only HIV-1 immunogens in rhesus monkeys. *J Virol*, 2012, 86: 11434-11440
- 16 Lai L, Kwa S F, Kozlowski P A, et al. SIVmac239 MVA vaccine with and without a DNA prime, similar prevention of infection by a repeated dose SIVsmE660 challenge despite different immune responses. *Vaccine*, 2012, 30: 1737-1745
- 17 Goepfert P A, Elizaga M L, Sato A, et al. Phase I safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. *J Infect Dis*, 2011, 203: 610-619
- 18 IAVIReport—The publication on AIDS vaccine research. <http://www.iavireport.org>, August 13, 2012
- 19 Saunders K O, Rudicell R S, Nabel G J. The design and evaluation of HIV-1 vaccines. *AIDS*, 2012, 26: 1293-1302
- 20 Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. *N Engl J Med*, 2009, 361: 2209-2220
- 21 van Druenen Littel-van den Hurk S, Hannaman D. Electroporation for DNA immunization: clinical application. *Expert Rev Vaccines*, 2010, 9: 503-517
- 22 Graham B S, Koup R A, Roederer M, et al. Phase I safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. *J Infect Dis*, 2006, 194: 1650-1660
- 23 Schadeck E B, Sidhu M, Egan M A, et al. A dose sparing effect by plasmid encoded IL-12 adjuvant on a SIVgag-plasmid DNA vaccine in rhesus macaques. *Vaccine*, 2006, 24: 4677-4687
- 24 Ganguly S, Liu J, Pillai V B, et al. Adjuvantive effects of anti-4-1BB agonist Ab and 4-1BBL DNA for a HIV-1 Gag DNA vaccine: different effects on cellular and humoral immunity. *Vaccine*, 2010, 28: 1300-1309
- 25 Spearman P, Kalams S, Elizaga M, et al. Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial. *Vaccine*, 2009, 27: 243-249
- 26 Girard M P, Osmanov S, Assossou O M, et al. Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: a review. *Vaccine*, 2011, 29: 6191-6218
- 27 Oxenius A, Martinic M M, Hengartner H, et al. CpG-containing oligonucleotides are efficient adjuvants for induction of protective antiviral immune responses with T-cell peptide vaccines. *J Virol*, 1999, 73: 4120-4126
- 28 Gallichan W S, Woolstencroft R N, Guarasci T, et al. Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex

- virus-2 in the genital tract. *J Immunol*, 2001, 166: 3451–3457
- 29 Belyakov I M, Isakov D, Zhu Q, et al. Enhancement of CD8⁺ T cell immunity in the lung by CpG oligodeoxynucleotides increases protective efficacy of a modified vaccinia Ankara vaccine against lethal poxvirus infection even in a CD4-deficient host. *J Immunol*, 2006, 177: 6336–6343
 - 30 Olvera-Gomez I, Hamilton S E, Xiao Z, et al. Cholera toxin activates nonconventional adjuvant pathways that induce protective CD8 T-cell responses after epicutaneous vaccination. *Proc Natl Acad Sci USA*, 2012, 109: 2072–2077
 - 31 Elena Gomez C, Perdiguero B, Garcia-Arriaza J, et al. Poxvirus vectors as HIV/AIDS vaccines in humans. *Hum Vaccin Immunother*, 2012, 8: 1192–1207
 - 32 Makitalo B, Lundholm P, Hinkula J, et al. Enhanced cellular immunity and systemic control of SHIV infection by combined parenteral and mucosal administration of a DNA prime MVA boost vaccine regimen. *J Gen Virol*, 2004, 85: 2407–2419
 - 33 Bertley F M, Kozlowski P A, Wang S W, et al. Control of simian/human immunodeficiency virus viremia and disease progression after IL-2-augmented DNA-modified vaccinia virus Ankara nasal vaccination in nonhuman primates. *J Immunol*, 2004, 172: 3745–3757
 - 34 Manrique M, Micewicz E, Kozlowski P A, et al. DNA-MVA vaccine protection after X4 SHIV challenge in macaques correlates with day-of-challenge antiviral CD4⁺ cell-mediated immunity levels and postchallenge preservation of CD4⁺ T cell memory. *AIDS Res Hum Retroviruses*, 2008, 24: 505–519
 - 35 Sandstrom E, Nilsson C, Hejdeman B, et al. Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara. *J Infect Dis*, 2008, 198: 1482–1490
 - 36 Bakari M, Aboud S, Nilsson C, et al. Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania. *Vaccine*, 2011, 29: 8417–8428
 - 37 Gorse G J, Newman M J, deCamp A, et al. DNA and modified vaccinia virus Ankara vaccines encoding multiple cytotoxic and helper T-lymphocyte epitopes of human immunodeficiency virus type 1 (HIV-1) are safe but weakly immunogenic in HIV-1-uninfected, vaccinia virus-naïve adults. *Clin Vaccine Immunol*, 2012, 19: 649–658
 - 38 Shen Z W, Jin H T, Li C, et al. Adjuvant effects of dual costimulatory molecules on cellular responses to HIV multipleepitope DNA vaccination. *Chem Res Chin Univ*, 2009, 25: 347–352
 - 39 McBurney S P, Ross T M. Viral sequence diversity: challenges for AIDS vaccine designs. *Expert Rev Vaccines*, 2008, 7: 1405–1417
 - 40 Hatzioannou T, Ambrose Z, Chung N P, et al. A macaque model of HIV-1 infection. *Proc Natl Acad Sci USA*, 2009, 106: 4425–4429
 - 41 Flynn N M, Forthal D N, Harro C D, et al. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. *J Infect Dis*, 2005, 191: 654–665
 - 42 Schneider J, Gilbert S C, Blanchard T J, et al. Enhanced immunogenicity for CD8⁺ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. *Nat Med*, 1998, 4: 397–402
 - 43 Liu M A. Immunologic basis of vaccine vectors. *Immunity*, 2010, 33: 504–515
 - 44 Liu L, Hao Y, Luo Z, et al. Broad HIV-1 neutralizing antibody response induced by heterologous gp140/gp145 DNA prime-vaccinia boost immunization. *Vaccine*, 2012, 30: 4135–4143
 - 45 Hel Z, Nacsa J, Trynieszewska E, et al. Containment of simian immunodeficiency virus infection in vaccinated macaques: correlation with the magnitude of virus-specific pre- and postchallenge CD4⁺ and CD8⁺ T cell responses. *J Immunol*, 2002, 169: 4778–4787
 - 46 Mascola J R, Sambor A, Beaudry K, et al. Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins. *J Virol*, 2005, 79: 771–779
 - 47 Koup R A, Roederer M, Lamoreaux L, et al. Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses. *PLoS ONE*, 2010, 5: e9015
 - 48 Schell J, Rose N F, Fazo N, et al. Long-term vaccine protection from AIDS and clearance of viral DNA following SHIV89.6P challenge. *Vaccine*, 2009, 27: 979–986
 - 49 Shephard E, Burgers W A, Van Harmelen J H, et al. A multigene HIV type 1 subtype C modified vaccinia Ankara (MVA) vaccine efficiently boosts immune responses to a DNA vaccine in mice. *AIDS Res Hum Retroviruses*, 2008, 24: 207–217
 - 50 Esteban M. Attenuated poxvirus vectors MVA and NYVAC as promising vaccine candidates against HIV/AIDS. *Hum Vaccin*, 2009, 5: 867–871
 - 51 Boukhebbaz H, Bellon N, Limacher J M, et al. Therapeutic vaccination to treat chronic infectious diseases: current clinical developments using MVA-based vaccines. *Hum Vaccin Immunother*, 2012, 8
 - 52 Garcia F, Bernaldo de Quiros J C, Gomez C E, et al. Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: a phase I clinical trial (RISVAC02). *Vaccine*, 2011, 29: 8309–8316

Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.